Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
2021 Cell & Gene Therapy Report
2021 Monoclonal Antibody & Recombinant Protein Market Report
2022 Sterile Drug Market Report
2022 API Market Report
2022 OSD Market Report
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Alzheimer’s Disease
29 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
Neurodegenerative Disease Clinical Trials
Preparing for Growth in Neurodegenerative Treatment Opportunities: How Clinical Teams can Best Position Study Design and Strategy to Reach Study Participants
PAO-09-022-CL-09
Alzheimer's Diagnostic Test
FDA Permits Marketing for New Test to Improve Diagnosis of Alzheimer's Disease
PR-M05-22-02
Column: New Drug Watch
Alzheimer Drug Still Controversial
PAO-03-022-NI-04
Alzheimer's Vaccine
Araclon Biotech Advances in Its Innovative Vaccine and Diagnostic Test for Alzheimer's
PR-M03-22-06
Alzheimer's Disease
Early Targeting of Chronic Inflammation That Precedes and Causes Synaptic Loss
PTV-07-21-CL-001
FDA Approval
FDA Grants Accelerated Approval for Aduhelm™ as the First and Only Alzheimer’s Disease Treatment to Address a Defining Pathology of the Disease
PR-M06-21-015
Stem Cells
Changing the Paradigm of Stem Cell Technology
PAP-Q4-20-CL-008
Alzheimer's Disease
The Self-Protein Challenge
PAP-Q4-19-CL-002
Alzheimer's Disease
Innovating the Approach to Neurological Disease Treatment
PAP-Q4-19-CL-004
Funding
T3D Therapeutics Closes $15M Financing to Advance Phase 2 Development of T3D-959 in a New Approach to Treating Alzheimer's Disease
PR-M11-19-NI-001
Prevention
Could Preventing the Development of Amyloid Beta Lesions in the Brain Stop Alzheimer’s?
PAO-M09-19-NI-012
Research
New Alzheimer’s Test Could be on the Horizon
PAO-M08-19-NI-011
Appointment
Eisai Inc. Deepens Its Commitment to Alzheimer's Disease with Key Executive Appointments
PR-M05-19-NI-015
Phase 3 Data
Avanir Pharmaceuticals, Inc. Reports Phase 3 Data of AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia
PR-M03-19-NI-080
Research
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease
PR-M03-19-NI-067
Machine Learning
Machine Learning May Benefit Future Alzheimer’s Patients
PAO-M03-19-NI-022
FDA
FDA Moves Against Companies Claiming Treatments for Alzheimer’s Disease
PAO-M02-19-NI-013
Alzheimer's Disease
Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease
PR-M02-19-NI-001
Alzheimer's Disease
Public Supports NIH Grants for Alzheimer's Microbes, Reports Alzheimer's Germ Quest, Inc.
PR-M12-18-NI-071
Alzheimer's Disease
First Drug Candidate From Eisai-UCL Research Collaboration To Enter Alzheimer's Disease Clinical Trials
PR-M12-18-NI-037
Alzheimer's Disease
Ocular Technology Provides Early Detection of Alzheimer's Disease
PR-M12-18-NI-014
Research
Researchers Discover Potential Cause for Alzheimer’s Disease
PAO-M11-18-NI-028
Research
New Finding Adds Proof Microbes are at Alzheimer's "Crime Scene," Says Dr. Leslie Norins, CEO of Alzheimer's Germ Quest, Inc.
PR-M11-18-NI-062
Antibody Treatment
BioArctic Obtains Exclusive Rights to Develop Antibody Treatments for Alzheimer's Disease from a Research Project Jointly Owned with Eisai
PR-M08-18-NI-090
1
2
»
